Soligenix, Inc. Share Price

SNGX

US8342236044

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 02:30:00 07/02/2026 am IST			5-day change	1st Jan Change
1.130 ^USD	+8.65%		-9.60%	-15.67%

24/01	Soligenix enters sales agreement with Rodman	RE
18/12	Soligenix, Inc. Announces Positive Clinical Results from Phase 2 Trial of Sgx945 for the Treatment of Behcet's Disease Published in Rheumatology	CI

Analysts' recommendations: Soligenix, Inc.

07/25/07	Soligenix achieves important safety milestone in its confirmatory phase 3 Clinical Trial of HyBryte(TM) for the treatment of cutaneous T-cell lymphoma	RE
30/25/30	Soligenix says on Sept 25, entered securities purchase agreement with investors - SEC filing	RE
30/25/30	Soligenix announces closing of $7.5 million public offering	RE
25/21/25	SOLIGENIX : Alliance Global Adjusts Price Target on Soligenix to $3.75 From $5.75, Reiterates Buy Rating	MT
01/21/01	SOLIGENIX : B. Riley Lowers Soligenix' PT to $1.50 from $2 on Unchanged Valuation Methodology, Keeps Neutral Rating	MT

More recommendations

Press Releases: Soligenix, Inc.

19/12	Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behcet's Disease Published in Rheumatology (Oxford)	AQ
17/12	Soligenix : Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis	PU
05/12	Soligenix Inc. (NASDAQ: SNGX) Advancing Rare-Disease Therapies Positioned at Pivotal Crossroad	GL
03/12	Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space	GL
19/25/19	Soligenix : Corporate Presentation	PU

More press releases

Managers and Directors: Soligenix, Inc.

Manager	Title	Age	Since
Christopher Schaber CEO	Chief Executive Officer	59	01/08/2006
Jonathan Guarino DFI	Director of Finance/CFO	53	11/09/2019
Richard Straube CTO	Chief Tech/Sci/R&D Officer	74	06/01/2014

Director	Title	Age	Since
Christopher Schaber CHM	Chairman	59	08/10/2009
Gregg Lapointe BRD	Director/Board Member	67	01/03/2009
Robert Rubin BRD	Director/Board Member	80	01/10/2009

More insiders

Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Its Specialized BioTherapeutics segment is developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). Development programs in this segment also include expansion of synthetic hypericin (SGX302) into psoriasis and dusquetide (SGX942 and SGX945) for the treatment of inflammatory diseases. Its Public Health Solutions segment includes development programs for RiVax, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease and its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax, its vaccine candidate for the prevention of COVID-19.

Employees

Sector

Biotechnology & Medical Research

Calendar

31/03 - Q4 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
06/26/06	1.130 $	+8.65%	1,49,617
05/26/05	1.040 $	-10.34%	3,13,560
04/26/04	1.160 $	-5.69%	2,18,893
03/26/03	1.230 $	0.00%	1,81,635
02/26/02	1.230 $	-1.60%	1,23,687

Delayed Quote Nasdaq, February 07, 2026 at 02:30 am IST

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.130USD

Average target price

17.50USD

Spread / Average Target

+1,448.67%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

The best tools reserved for subscribers to boost the performance of your investments!

Capitalization	1.14Cr 96.48L 88.42L 83.75L 1.56Cr 103.26Cr 1.63Cr 10Cr 4.07Cr 50Cr 4.27Cr 4.19Cr 178.94Cr	P/E ratio 2025 *	-0.53x	P/E ratio 2026 *	-1.39x
Enterprise value	1.14Cr 96.48L 88.42L 83.75L 1.56Cr 103.26Cr 1.63Cr 10Cr 4.07Cr 50Cr 4.27Cr 4.19Cr 178.94Cr	EV / Sales 2025 *	-	EV / Sales 2026 *	22.8x
Free-Float	99.97%	Yield 2025 *	-	Yield 2026 *	-

1 day	+8.65%
1 week	-9.60%
Current month	-9.60%
1 month	-21.53%
3 months	-17.52%
6 months	-61.03%
Current year	-15.67%

1 week	1.02	1.25
1 month	1.02	1.46
Current year	1.02	1.49
1 year	1.02	6.23
3 years	1.02	92.88
5 years	1.02	595.2
10 years	1.02	2,292

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
SOLIGENIX, INC.	+8.65%	-9.60%	-51.08%	-98.98%	1.14Cr
ARGENX SE	-2.85%	-1.17%	+10.06%	+97.78%	5.03TCr
WUXI APPTEC CO., LTD.	+0.74%	+2.76%	+68.18%	+7.83%	4.21TCr
INSMED INCORPORATED	-0.77%	-4.47%	+87.44%	+656.87%	3.2TCr
BIONTECH SE	+1.02%	-6.27%	-9.34%	-24.46%	2.68TCr
WUXI BIOLOGICS (CAYMAN) INC.	+1.38%	+6.53%	+75.23%	-41.86%	1.99TCr
GENMAB A/S	-1.48%	-3.17%	+41.37%	-27.56%	1.91TCr
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-0.71%	+4.74%	+131.77%	-	1.26TCr
AKESO, INC.	+0.20%	+0.20%	+56.62%	+116.95%	1.19TCr
Average	+0.69%	-2.73%	+45.58%	+85.82%	2.39TCr
Weighted average by Cap.	-0.54%	-1.22%	+49.14%	+126.79%

	2025 *	2026 *
Net sales	-	5L 4L 4L 4L 7L 4.53Cr 7L 45.08L 17.85L 2.18Cr 18.75L 18.37L 7.85Cr
Net income	-1.12Cr -94.96L -87.03L -82.43L -1.53Cr -101.63Cr -1.6Cr -10Cr -4Cr -49Cr -4.21Cr -4.12Cr -176.12Cr	-1.01Cr -85.5L -78.36L -74.21L -1.38Cr -92Cr -1.44Cr -9.11Cr -3.6Cr -44Cr -3.79Cr -3.71Cr -158.57Cr
Net Debt	-	-

Soligenix, Inc. Share Price

Equities

SNGX

US8342236044

Biotechnology & Medical Research

Valuation: Soligenix, Inc.

Chart: Soligenix, Inc.

Latest news: Soligenix, Inc.

Analysts' recommendations: Soligenix, Inc.

Press Releases: Soligenix, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Soligenix, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise